Andreas R.
- Country
- Germany
- Department
- Universitätsklinikum Augsburg, II. Medizinische Klinik-Hämatologie, Onkologie
Research Overview
- Phase 1/2 Study of Subcutaneous Blinatumomab in Adults and Adolescents with Relapsed/Refractory or MRD+ B-cell Precursor Acute Lymphoblastic Leukemia
- Phase 3 Study of Oral Arsenic Trioxide QTX-2101 in Newly Diagnosed Low-Risk Acute Promyelocytic Leukemia
- INDIE: Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Data & Insights
Has run more than one trial at 109 of 310 partner sites.
Specializations
Lymphoma Research
Specializes in innovative therapeutic approaches for classical Hodgkin lymphoma, with particular focus on early-stage unfavorable and advanced disease states. The investigator explores individualized immunotherapy strategies and novel treatment combinations.
- PET-guided treatment protocols
- Checkpoint inhibition therapy
- Advanced stage treatment optimization
Acute Leukemia Studies
Conducts research in various forms of leukemia, including T-cell acute lymphoblastic leukemia, Philadelphia-chromosome positive ALL, and acute myeloid leukemia. Investigates novel therapeutic combinations and targeted approaches.
- CD38-positive disease treatment
- Tyrosine kinase inhibitor therapy
- Salvage treatment strategies
Myelodysplastic Syndrome Research
Focuses on therapeutic interventions for higher-risk myelodysplastic syndrome, including investigation of novel drug combinations and pre-transplant conditioning approaches.
- RARA-positive MDS treatment
- Stem cell transplantation preparation
- Combination therapy assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.